# US 2015/0072957 A1 · Tazobactam Arginine Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0072957 A1
- Document ID: US20150072957A1
- Status: Published application
- Kind: A1
- Application number: 14/541,890
- Filed: 2014-11-14
- Published: 2015-03-12
- Earliest claimed: 2012-09-27
- Assignees: Calixa Therapeutics, Inc.
- Applicants: Calixa Therapeutics, Inc.
- Inventors: Jan-Ji Lai; Jian-Qiao Gu; Pradip M. Pathare; Valdas Jurkauskas; Joseph Terracciano; Nicole Miller Damour
- Web page: https://patentgrep.com/patent/US20150072957A1

## CPC

- C07D 499/897: Compounds with substituents other than a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, directly attached in position 2
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/431: containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A61K 31/4353: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- C07D 499/14: Preparation of salts
- C07D 499/86: with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions.

## Claims

### Claim 1

A pharmaceutical composition comprising a compound having a beta-lactam chemical sub-structure and crystalline tazobactam arginine polymorph Ia.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, prepared by lyophilization.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, obtained from an aqueous solution comprising L-arginine and tazobactam acid.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the aqueous solution has a pH of about 5.9 to about 10.5 prior to lyophilization.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the beta-lactam compound is (2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the beta-lactam compound is selected from the group consisting of the compounds in Table 2:
TABLE 2
No.
IUPAC Name
CAS No.
1
(2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-
61477-96-1
phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-
2-carboxylic acid
2
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-
61-33-6
zabicyclo[3.2.0]heptane-2-carboxylic acid
3
(5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-
74431-23-5
7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
4
(5R,6S)-6-((R)-1-hydroxyethyl)-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-
106560-14-9
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid faropenem
5
(2S,5R,6R)-6-{[3-(2-chlorophenyl)-5-methyl-oxazole-4-carbonyl]amino}-
61-72-3
3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-
72558-82-8
yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-
bicyclo[4.2.0] oct-2-ene-2-carboxylate
7
(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-
63527-52-6
(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid
8
(6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-
400827-46-5
3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-
yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
9
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-
88040-23-7
3-((1-methylpyrrolidinium-1-yl)methyl)-8-oxo-5-thia-1-aza-
bicyclo[4.2.0]oct-2-ene-2-carboxylate
10
(6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-{[(2Z)-2-(2-furyl)-2-
55268-75-2
(methoxyimino) acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylic acid
11
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-
73384-59-5
(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-
1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylic acid
12
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)-acetyl]amino}-3,3-
26787-78-0
dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
13
3-[5-(dimethylcarbamoyl) pyrrolidin-2-yl] sulfanyl-6-(1-hydroxyethyl)-4-
119478-56-7
methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier or diluent.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, formulated for intravenous injection or infusion.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, having a molar ratio of about 1:1 between tazobactam acid and arginine.

### Claim 10

A pharmaceutical composition obtained from a solution formed by dissolving a compound having a beta-lactam chemical sub-structure and crystalline tazobactam arginine polymorph Ia.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, obtained by a process comprising lyophilizing the solution to obtain pharmaceutical composition.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein the solution comprises L-arginine and tazobactam acid.

### Claim 13 (depends on 10)

The pharmaceutical composition of claim 10, wherein the beta-lactam compound is (2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, wherein the solution has a pH of about 5.9 to about 10.5 prior to lyophilization.

### Claim 15 (depends on 10)

The pharmaceutical composition of claim 10, wherein the beta-lactam compound is selected from the group consisting of the compounds in Table 2:
TABLE 2
No.
IUPAC Name
CAS No.
1
(2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-
61477-96-1
phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-
2-carboxylic acid
2
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-
61-33-6
zabicyclo[3.2.0]heptane-2-carboxylic acid
3
(5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-
74431-23-5
7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
4
(5R,6S)-6-((R)-1-hydroxyethyl)-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-
106560-14-9
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid faropenem
5
(2S,5R,6R)-6-{[3-(2-chlorophenyl)-5-methyl-oxazole-4-carbonyl]amino}-
61-72-3
3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-
72558-82-8
yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-
bicyclo[4.2.0] oct-2-ene-2-carboxylate
7
(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-
63527-52-6
(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid
8
(6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-
400827-46-5
3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-
yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
9
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-
88040-23-7
3-((1-methylpyrrolidinium-1-yl)methyl)-8-oxo-5-thia-1-aza-
bicyclo[4.2.0]oct-2-ene-2-carboxylate
10
(6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-{[(2Z)-2-(2-furyl)-2-
55268-75-2
(methoxyimino) acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylic acid
11
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-
73384-59-5
(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-
1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylic acid
12
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)-acetyl]amino}-3,3-
26787-78-0
dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
13
3-[5-(dimethylcarbamoyl) pyrrolidin-2-yl] sulfanyl-6-(1-hydroxyethyl)-4-
119478-56-7
methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

### Claim 16

A pharmaceutical composition obtained by combining a compound having a beta-lactam chemical sub-structure selected from compounds in Table 2 and a tazobactam composition obtained from a solution formed by dissolving a crystalline tazobactam arginine polymorph Ia:
TABLE 2
No.
IUPAC Name
CAS No.
1
(2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-
61477-96-1
phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-
2-carboxylic acid
2
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-
61-33-6
zabicyclo[3.2.0]heptane-2-carboxylic acid
3
(5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-
74431-23-5
7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
4
(5R,6S)-6-((R)-1-hydroxyethyl)-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-
106560-14-9
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid faropenem
5
(2S,5R,6R)-6-{[3-(2-chlorophenyl)-5-methyl-oxazole-4-carbonyl]amino}-
61-72-3
3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-
72558-82-8
yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-
bicyclo[4.2.0] oct-2-ene-2-carboxylate
7
(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-
63527-52-6
(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid
8
(6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-
400827-46-5
3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-
yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
9
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-
88040-23-7
3-((1-methylpyrrolidinium-1-yl)methyl)-8-oxo-5-thia-1-aza-
bicyclo[4.2.0]oct-2-ene-2-carboxylate
10
(6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-{[(2Z)-2-(2-furyl)-2-
55268-75-2
(methoxyimino) acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylic acid
11
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-
73384-59-5
(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-
1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylic acid
12
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)-acetyl]amino}-3,3-
26787-78-0
dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
13
3-[5-(dimethylcarbamoyl) pyrrolidin-2-yl] sulfanyl-6-(1-hydroxyethyl)-4-
119478-56-7
methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the solution is an aqueous solution, and the tazobactam composition is obtained by a process comprising lyophilizing an aqueous solution comprising the crystalline tazobactam arginine polymorph Ia to obtain a lyophilized tazobactam composition, and combining the tazobactam composition.

### Claim 18 (depends on 16)

The pharmaceutical composition of claim 16, wherein the solution comprises L-arginine and tazobactam acid.

### Claim 19 (depends on 16)

The pharmaceutical composition of claim 16, wherein the beta-lactam compound is (2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.

### Claim 20 (depends on 17)

The pharmaceutical composition of claim 17, wherein the solution has a pH of about 5.9 to about 10.5 prior to lyophilization.

### Claim 21

A pharmaceutical composition comprising a tazobactam composition obtained from a solution formed by dissolving a tazobactam acid in an aqueous solution and lyophilizing the solution to obtain the tazobactam composition.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, obtained by a process further comprising the step of combining a compound having a beta-lactam chemical sub-structure selected from compounds in Table 2 with the tazobactam composition:
TABLE 2
No.
IUPAC Name
CAS No.
1
(2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-
61477-96-1
phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-
2-carboxylic acid
2
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-
61-33-6
zabicyclo[3.2.0]heptane-2-carboxylic acid
3
(5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-
74431-23-5
7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
4
(5R,6S)-6-((R)-1-hydroxyethyl)-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-
106560-14-9
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid faropenem
5
(2S,5R,6R)-6-{[3-(2-chlorophenyl)-5-methyl-oxazole-4-carbonyl]amino}-
61-72-3
3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-
72558-82-8
yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-
bicyclo[4.2.0] oct-2-ene-2-carboxylate
7
(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-
63527-52-6
(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid
8
(6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-
400827-46-5
3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-
yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
9
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-
88040-23-7
3-((1-methylpyrrolidinium-1-yl)methyl)-8-oxo-5-thia-1-aza-
bicyclo[4.2.0]oct-2-ene-2-carboxylate
10
(6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-{[(2Z)-2-(2-furyl)-2-
55268-75-2
(methoxyimino) acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylic acid
11
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-
73384-59-5
(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-
1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylic acid
12
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)-acetyl]amino}-3,3-
26787-78-0
dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
13
3-[5-(dimethylcarbamoyl) pyrrolidin-2-yl] sulfanyl-6-(1-hydroxyethyl)-4-
119478-56-7
methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the solution further comprises L-arginine.

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein the solution has a pH of about 5.9 to about 10.5 prior to lyophilization.

### Claim 25 (depends on 22)

The pharmaceutical composition of claim 22, wherein the beta-lactam compound is (2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.
